Somebody had to pay the price for the HBOC acquisition,

All this consolidation could rekindle talks between everybody.

With all the price competition [in generics], we're likely to see more consolidation.

It's tougher this year for the prescription allergy drugs.

I still see solid earnings growth for the sector. Growth looks strong especially when you consider (expected sector) growth of 13-to-14 percent, compared to an (expected) S&P 500 drop of about 7-to-8 percent.

Schering-Plough is hanging in there.